Fundz

Lobe Sciences Ltd. Appoints Yong Yao as Chief Financial Officer

PRIVATEJun 03, 2025

Position

Vice President

Company

Lobe Sciences

Yong Yao
BiotechnologyHealth CareMedicalTherapeutics

Description

Lobe Sciences Ltd has appointed Mr Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025. Mr Yao brings over 25 years of extensive experience in finance and biotech, crucial for guiding the company's financial strategy.

Quick answer

Lobe Sciences Ltd. Appoints Yong Yao as Chief Financial Officer (June 3, 2025).

Who is the new Vice President at Lobe Sciences?
Lobe Sciences named Yong Yao Vice President, announced June 3, 2025.
What did Lobe Sciences announce on June 3, 2025?
Lobe Sciences Ltd has appointed Mr Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025. Mr Yao brings over 25 years of extensive experience in finance and biotech, crucial for guiding the company's financial strategy.
What does Lobe Sciences do?
Lobe Sciences is a biopharmaceutical company dedicated to advancing innovative technologies for the development of urgently needed treatments for orphan and rare diseases.
Which similar companies made leadership changes around the same time?
Elite Clinical Network (ECN) (June 2, 2025), Wave Life Sciences (May 28, 2025), Vivex Biologics (June 10, 2025) and Hansa Biopharma (May 13, 2025) also announced leadership changes within 45 days of Lobe Sciences.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Lobe Sciences, and when

A new leader at Lobe Sciences brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Lobe Sciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lobe Sciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lobe Sciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lobe Sciences

About

Lobe Sciences is a biopharmaceutical company dedicated to advancing innovative technologies for the development of urgently needed treatments for orphan and rare diseases. The company commercializes Altemia® MF, a medical food formulated to address deficiencies commonly associated with sickle cell disease. Additionally, Lobe Sciences is developing S100, an orphan drug candidate aimed at treating sickle cell disease. Through Cynaptec, Lobe maintains an interest in the development of Conjugated Psilocin™, targeting neurology and psychiatric conditions. The company also retains Alera Pharma, Inc. as a wholly owned subsidiary, which may be utilized for future initiatives unrelated to Conjugated Psilocin™.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lobe Sciences changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

David
Senior decision-maker at this company
••••••••@••••••••

See David's verified email →

David
Senior decision-maker at this company
••••••••@••••••••

See David's verified email →

Andrew
Senior decision-maker at this company
••••••••@••••••••

See Andrew's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Lobe Sciences's next move

Learn about Strategic plan

Lobe Sciences changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.